International Scientific Conference • Translational Medicine • Biotechnology • Clinical Strategy | Dates: 20–22 January 2027 | Venue: Singapore
participation@executivecongresses.com Submit Abstract
ECTMBICS 2027 logo
ECTMBICS 2027
Programme • Singapore
Keynotes • Oral presentations • Posters • Clinical translation • Biotech innovation

Official Programme 11th Executive Congress on Translational Medicine, Biotech Innovation & Clinical Strategy

The ECTMBICS 2027 programme brings together keynote lectures, scientific presentations, poster contributions, clinical perspectives, and interdisciplinary discussion across translational medicine, biotechnology, and clinical strategy. Each oral presentation is allocated dedicated presentation and discussion time. A focused poster session takes place on Day 2 after the tea break, while the formal scientific programme concludes before lunch on Day 3 to allow extended networking and collaboration. Additional oral and poster presentation opportunities remain available.

Day 1 Day 2 Day 3
Congress overview

A focused international format combining scientific presentations, clinical perspectives, biotech innovation, industry exchange, professional networking, and collaborative discussion across healthcare and life sciences.

Presentation spots available
Dates
20–22 January 2027
Location
Singapore
See venue details
Participation model
Abstract → Acceptance → Registration
Delegates may register without submitting an abstract
Submit Abstract → Register
Business Address: 98 Theobalds Rd, London WC1X 8WB, UK
Conference format
Focused & interactive

A carefully structured conference environment designed to support meaningful discussion, presenter interaction, and professional networking.

Programme structure
Balanced scientific format

Opening sessions, keynote lectures, oral presentations, poster interaction, scientific exchange, collaboration, and dedicated networking are integrated across the programme.

Core focus
Discovery to impact

Clinical translation, trials, digital health, regulatory science, pharma strategy, and healthcare commercialisation.

Designed outcome
Exchange & collaboration

Scientific discussion, interdisciplinary networking, research collaboration, industry connections, and practical pathways from discovery to clinical impact.

Programme opportunities remain open

Presentation opportunities remain available

The scientific programme continues to accept suitable oral and poster contributions. Additional submissions can be accommodated through the conference's flexible parallel-session format while maintaining dedicated time for discussion and interaction.

Submit Abstract → Register
Day 1 • Wednesday, 20 January 2027

Opening Ceremony, Keynote Lectures, Scientific Sessions & Networking

The opening day establishes the scientific direction of the congress through keynote lectures, parallel scientific presentations, poster interaction, and the welcome networking reception.

Opening & keynote programme
08:00–09:00
Registration & Welcome Coffee

Participant registration, conference materials, welcome assistance, and informal networking.

09:00–09:30
Opening Ceremony & Welcome Address

Opening remarks, conference objectives, programme overview, and introduction to the three-day scientific meeting.

09:30–10:00
30 minutes
Keynote 01
Mr. Barry Balfe
CEO, ICON Pharma Development Solutions
From Development Strategy to Global Clinical Execution: Building Effective Pharma Partnerships
30-minute keynote slot including presentation and discussion/Q&A.
10:00–10:30
30 minutes
Keynote 02
Prof. Han-Chung Wu
Biomedical Translation Research Center (BioTReC), Taiwan
Advancing Biomedical Translation from Discovery Platforms to Clinical Applications
30-minute keynote slot including presentation and discussion/Q&A.
10:30–11:00
30 minutes
Keynote 03
Matthew Hewitt
Charles River Laboratories
Preclinical Models and Translational Pathways for Next-Generation Therapeutics
30-minute keynote slot including presentation and discussion/Q&A.
11:00–11:30
Coffee Break & Networking

Refreshments and discussion with keynote speakers, presenters, delegates, and participating organisations.

11:30–12:00
30 minutes
Keynote 04
Prof. Lani Wu
University of California, San Francisco
Systems-Level Approaches to Translational Medicine and Biomedical Discovery
30-minute keynote slot including presentation and discussion/Q&A.
12:00–12:30
30 minutes
Keynote 05
Dr. Feng-Chi Chen
Institute of Population Health Sciences, National Health Research Institutes
Population Health Evidence and Implementation Pathways for Clinical Translation
30-minute keynote slot including presentation and discussion/Q&A.
12:30–13:00
30 minutes
Keynote 06
Marc Goemans
Chief Commercial Officer, Bora Biologics
Biologics Manufacturing, Commercial Strategy and Global Partnership Models
30-minute keynote slot including presentation and discussion/Q&A.
13:00–14:00
Networking Lunch

Open-seating lunch supporting interdisciplinary, international, academic, clinical, and industry connections.

14:00–16:00 • Parallel Scientific Sessions

Confirmed Scientific Presentations

Confirmed scientific presentations are scheduled across parallel rooms, with each speaker receiving a dedicated presentation and discussion slot.

Parallel Room A

Scientific Presentations — Room A

Parallel session
14:00–14:30
30 min
Confirmed Presentation 01
Fuzhong Li
Oregon Research Institute, USA
Transforming tai ji quan into next-generation, evidence-based exercise medicine: A translational roadmap for falls prevention
14:30–15:00
30 min
Confirmed Presentation 02
Qiya Wang
Jiao Tong University School of Medicine, China
Traditional chinese medicine monomers in dry eye disease: Pharmacological mechanisms, tear film stability, and translational challenges
15:00–15:30
30 min
Confirmed Presentation 03
Hrithiha Sriramulu
Duke University, USA
Translational cell fate reprogramming and regenerative medicine enabled by microphysiological systems
15:30–16:00
30 min
Confirmed Presentation 04
L.M. Bosman
University of Pretoria, South Africa
Translational human and equine regenerative medicine in musculoskeletal conditions
Parallel Room B

Scientific Presentations — Room B

Parallel session
14:00–14:30
30 min
Confirmed Presentation 05
Megan Crooks
University of Manitoba, Canada
Medical Extended Reality in Perioperative Medicine: A Scoping Review of Intervention Development, Feasibility Evaluation, and Translational Readiness
14:30–15:00
30 min
Confirmed Presentation 06
Andrea M. Krenek
University of Florida, USA
Behavioral Frameworks and Translational Applications of Culinary Medicine and Culinary Nutrition
15:00–15:30
30 min
Confirmed Presentation 07
Giancarlo Lauto
University of Udine, Italy
The knowledge production model of the New Sciences: The case of Translational Medicine
15:30–16:00
30 min
Confirmed Presentation 08
Will Ray
Marshfield Clinic Research Foundation, USA
MD-CTS: An integrated terminology reference of clinical and translational medicine
16:00–16:30
Refreshment Break

Coffee, refreshments, and informal networking.

16:30–17:45
Poster Showcase & Scientific Networking

Dedicated poster viewing, author interaction, emerging-research discussion, and networking across translational medicine, biotechnology, clinical research, and healthcare innovation.

17:45–18:30
Welcome Networking Reception

Informal networking reception for keynote speakers, presenters, delegates, partners, and invited guests.

Day 2 • Thursday, 21 January 2027

Keynote Lectures, Scientific Presentations, Poster Session & Collaboration

Day 2 combines keynote lectures and parallel scientific presentations, followed by a dedicated poster session after the tea break and an evening forum for research collaboration and professional networking.

Scientific & poster programme
09:00–09:30
30 minutes
Keynote 07
Dr. Guillermo Del Angel
Center for Genomics Research, AstraZeneca
Genomics-Driven Precision Medicine: Translating Data into Therapeutic Insight
30-minute keynote slot including presentation and discussion/Q&A.
09:30–10:00
30 minutes
Keynote 08
Ed Deng
Co-Founder and CEO, Health2Sync
Digital Health Platforms for Patient Engagement, Monitoring and Clinical Outcomes
30-minute keynote slot including presentation and discussion/Q&A.
10:00–10:30
30 minutes
Keynote 09
Sanghoon Park
CEO, Illimis Therapeutics, Korea
Therapeutics Innovation and Biotech Leadership in Emerging Clinical Pipelines
30-minute keynote slot including presentation and discussion/Q&A.
10:30–11:00
Coffee Break & Scientific Networking

Refreshments and discussion among keynote speakers, presenters, delegates, clinicians, researchers, and industry participants.

11:00–13:00 • Parallel Scientific Sessions

Morning Oral Presentations

Scientific presentations are delivered across parallel rooms before the networking lunch.

Parallel Room A

Scientific Presentations — Room A

Parallel session
11:00–11:30
30 min
Confirmed Presentation 09
Carol Isaacson Barash
Helix Health Advisors, USA
Translating translational medicine into global health equity: What is needed?
11:30–12:00
30 min
Confirmed Presentation 10
Dinah M. Duarte
INFARMED, Portugal
The translational value of animal models in orphan medicines designations for rare paediatric neurological diseases
12:00–12:30
30 min
Confirmed Presentation 11
Peter Keating
University of Quebec at Montreal, Canada
“Triple negative breast cancer”: Translational research and the (re)assembling of diseases in post-genomic medicine
12:30–13:00
30 min
Confirmed Presentation 12
Kai LU
Chinese Center for Disease Control and Prevention, China
Transcontinental Translational Medicine Collaboration: A Successful Sino-Cuban Joint B-to-B Program
Parallel Room B

Scientific Presentations — Room B

Parallel session
11:00–11:30
30 min
Confirmed Presentation 13
John Orechia
Dana-Faber Cancer Institute,USA
OncDRS: An integrative clinical and genomic data platform for enabling translational research and precision medicine
11:30–12:00
30 min
Confirmed Presentation 14
Krzysztof Goryński
Nicolaus Copernicus University in Toruń, Poland
SPME as a promising tool in translational medicine and drug discovery: From bench to bedside
12:00–12:30
30 min
Confirmed Presentation 15
Tinneke Denayer
Ablynx NV, Dept. Pharmacology, Belgium
Animal models in translational medicine: Validation and prediction
12:30–13:00
30 min
Confirmed Presentation 16
Yomogi Shiota
Tokyo University of Agriculture and Technology, Japan
Derivation of a new model of lung adenocarcinoma using canine lung cancer organoids for translational research in pulmonary medicine
13:00–14:00
Networking Lunch

Lunch and open networking across academic, clinical, biotechnology, pharmaceutical, and healthcare communities.

14:00–15:00 • Parallel Scientific Sessions

Afternoon Oral Presentations

Further scientific presentations complete the Day 2 oral programme.

Parallel Room A

Scientific Presentations — Room A

Parallel session
14:00–14:30
30 min
Confirmed Presentation 17
Siu-Keung Keung
City University of Hong Kong
Statistical Tests for One-way/Two-way Translation in Translational Medicine
14:30–15:00
30 min
Confirmed Presentation 18
Shein Chung
Duke University School of Medicine, United States
Statistical Methods in Translational Medicine
Parallel Room B

Scientific Presentations — Room B

Parallel session
14:00–14:30
30 min
Confirmed Presentation 19
Xinkang Wang
Merck & Co., Inc., Rahway, United States
Multimodal Biomarker Investigation on Efficacy and Mechanism of Action for the Mammalian Target of Rapamycin Inhibitor, Temsirolimus, in a Preclinical Mammary Carcinoma OncoMouse Model: A Translational Medicine Study in Support for Early Clinical Development
14:30–15:00
30 min
Confirmed Presentation 20
Junqi Cui
University of New South Wales, Australia
From TCMBank to translational hypotheses: A machine-learning framework for prioritizing Chinese medicinal herbs for liver diseases
15:00–15:30
Refreshment Break

Coffee, refreshments, and informal discussion.

15:30–17:00 • Dedicated Poster Session

Poster Presentations & Author Interaction

A dedicated poster session follows the Day 2 tea break, bringing poster presenters together for direct discussion with authors, scientific exchange, and networking.

Dedicated poster session
Poster 01 Day 2
Lauren E. Smith
University of Southern Denmark, Denmark
A Temporal Phospho-acetylome Atlas of Human Myogenesis Identifies coordinated Post-Translational Regulation
Poster 02 Day 2
Stephen C. Purdy
University of Colorado Anschutz Medical Campus (AMC), USA
eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by small molecules
Poster 03 Day 2
Simon Couillard
Leiden University Medical Center, Netherlands
Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies
Poster 04 Day 2
Shi-Hong Ren
School of Medicine, Taizhou University, China
Could targeting the gut-liver-bone axis prevent both MASLD and osteoporosis? A translational scientific hypothesis
Poster 05 Day 2
Lee-Fong Yau
Macau University of Science and Technology, Macao
Age-related plasma N-glycosylation changes across humans, rats, and mice identify candidate glycan biomarkers for translational aging studies
Poster 06 Day 2
Nan Chen
The First Affiliated Hospital of Zhejiang Chinese Medical University, China
Targeting Grx1 by hyperoside regulates Ncf4 post-translational modification to enhance mitophagy and accelerate diabetic wound healing
Poster 07 Day 2
Christopher Kessler
Technical University of Munich (TUM), Germany
Development of a translational radiobiology platform using pancreatic cancer patient-derived organoids for personalized radiation oncology
Poster 08 Day 2
Piyan Zhang
Shanghai Medicilon Pharmaceutical Company, China
Nonclinical development of advanced therapies: Best practices for translational and regulatory success
Poster 09 Day 2
Jeeyeon Kim
Sungkyunkwan University, Republic of Korea
Synthesis and Translational Assessment of Trinucleotide 5′-Cap Analogs for Messenger Ribonucleic Acid-Based Therapeutics
Poster 10 Day 2
Shichao Li
Westlake University, China
Rationally designed light-inducible RNA-releasing protein for translational regulation and optogenetic control of gene therapies
Poster 11 Day 2
Renu Baweja
Shivaji College, University of Delhi, India
Role of post-translational modifications in virulence of Bacillus anthracis: A narrative review
Poster 12 Day 2
Fajin Li
School of Medicine, Westlake University, China
Translational resistance to amino acid starvation in breast cancer cells revealed by ribosome profiling
Poster 13 Day 2
Camille Boross
Bern University Hospital, University of Bern, Switzerland
Non-canonical phage–bacterium interactions during topical phage therapy in the PhagoBurn clinical trial: a retrospective, observational, reverse translational study
Poster 14 Day 2
Junling Gao
University of Chinese Academy of Sciences, China
4E-BP inhibition ameliorates heart failure through translational upregulation of SERCA2a and modulation of mitochondrial redox signaling in cardiomyocytes
Poster 15 Day 2
Xiaoxue Tian
The Second Hospital & Clinical Medical School, China
Preclinical Safety Evaluation and First-in-Human Translational Study of [177Lu]Lu-TEFAPI-06: An Albumin-Binding Fibroblast Activation Protein Inhibitor for Theranostics
Day 3 • Friday, 22 January 2027

Final Scientific Sessions, Closing & Networking Afternoon

The final scientific sessions are delivered in parallel rooms before the formal programme concludes at lunchtime, leaving the afternoon for networking, one-to-one meetings, and collaboration.

Scientific close before lunch
08:30–09:00
Morning Coffee & Networking

Arrival coffee, informal networking, and preparation for the final scientific sessions.

09:00–11:30 • Parallel Scientific Sessions

Final Morning Scientific Presentations

The final scientific presentations are delivered across parallel rooms, allowing the formal programme to conclude before lunch.

Parallel Room A

Final Scientific Presentations — Room A

Parallel session
09:00–09:30
30 min
Confirmed Presentation 21
Rodney J.Y. Ho
Department of Bioengineering, Seattle, United States
Trends in Translational Medicine and Drug Targeting and Delivery: New Insights on an Old Concept—Targeted Drug Delivery with Antibody–Drug Conjugates for Cancers
09:30–10:00
30 min
Confirmed Presentation 22
Benjamin DeSollar
University of Iowa, USA
The AudioGene Translational Dashboard for Diagnosing Autosomal Dominant Nonsyndromic Hearing Loss: Phenotypic Data Visualization and Analysis Study
10:00–10:30
30 min
Confirmed Presentation 23
Ataman Sendoel
University of Zurich, Switzerland
In vivo single-cell ribosome profiling reveals cell-type-specific translational programs during aging
10:30–11:00
30 min
Confirmed Presentation 24
Fan Zhang
Fudan University, China
Clinical and translational landscape of rare earth-based imaging and therapeutic agents
11:00–11:30
30 min
Confirmed Presentation 25
Peng Li
Chinese Academy of Sciences, China
Global mapping of circRNA-target RNA interactions reveal P-body-mediated translational repression
Parallel Room B

Final Scientific Presentations — Room B

Parallel session
09:00–09:30
30 min
Confirmed Presentation 26
Virginia Guzzeloni
Vita-Salute San Raffaele University, Italy
A viable human lung cancer tissue collection (LCTC) to accelerate translational research
09:30–10:00
30 min
Confirmed Presentation 27
Jennifer Sells
The University of Texas, USA
Enhancing Pathology Knowledge for Biomedical Scientists: Pilot Cohort Study of a Comprehensive Self-Paced Tutorial for Bridging Fundamental Concepts With Translational Applications
10:00–10:30
30 min
Confirmed Presentation 28
Lingci Huang
China Pharmaceutical University, China
mRNA translational dynamics mediates totipotent-like reprogramming
10:30–11:00
30 min
Confirmed Presentation 29
Eunbin Park
Kangwon National University, Republic of Korea
Post-translational chemical modification of E3 ligase for efficient target protein degradation
11:00–11:30
30 min
Confirmed Presentation 30
Siwei Xu
The Second Affiliated Hospital of Fujian Medical University, China
YTHDF1-mediated translational activation of SETD2 suppresses aerobic glycolysis and sensitizes renal cell carcinoma to sunitinib
11:30–12:00
Closing Remarks & Conference Acknowledgements

Closing reflections, participant acknowledgements, programme conclusion, and transition to the networking-focused afternoon.

12:00–13:00
Networking Lunch

Final conference lunch with open seating for scientific, clinical, academic, and industry networking.

13:00–15:30
Open Networking, One-to-One Meetings & Collaboration Time

The formal scientific programme is complete. The afternoon is reserved for optional networking, bilateral meetings, partnership discussions, research collaboration, and informal professional engagement.